Table 3.

Univariable and Multivariable Cox Regression of the combined 4-gene classifier, miR-21 expression and HOXA9 DNA methylation in two cohorts.

Combined Biomarker	Univariable			Multivariablea
	N	HR (95% CI)	P	HR (95% CI)	P
NCI/Norway cohort
0 (all low risk)	24	Reference		Reference
1 (one high risk)	30	2.66 (0.70–10.0)	0.149	2.11 (0.53–8.49)	0.291
2 (two high risk)	30	4.51 (1.29–15.7)	0.018	3.96 (1.07–14.7)	0.040
3 (all high risk)	7	12.0 (2.82–51.0)	0.001	18.5 (3.72–91.9)	4.E-04
		Trend P = 5.E-04		Trend P = 7.E-04
NCI/Norway cohort (therapy näive)
0 (all low risk)	18	Reference		Reference
1 (one high risk)	25	2.61 (0.53–12.9)	0.241	2.13 (0.37–12.1)	0.395
2 (two high risk)	25	4.35 (0.95–19.9)	0.058	5.23 (0.96–28.6)	0.056
3 (all high risk)	4	13.2 (2.17–80.4)	0.005	43.1 (4.52–411)	0.001
		Trend P = 0.005		Trend P = 0.002
Japan cohort (therapy näive)
0 (all low risk)	26	Reference		Reference
1 (one high risk)	36	0.21 (0.02–2.06)	0.183	0.25 (0.03–2.48)	0.239
2 (two high risk)	28	2.64 (0.70–9.94)	0.152	2.91 (0.75–11.3)	0.123
3 (all high risk)	23	6.51 (1.84–22.9)	0.004	6.22 (1.74–22.2)	0.005
		Trend P = 3.E-05		Trend P = 0.0001
Combined cohort (therapy näive)
0 (all low risk)	44	Reference		Reference
1 (one high risk)	61	1.01 (0.32–3.17)	0.992	0.75 (0.23–2.47)	0.633
2 (two high risk)	53	3.37 (1.25–9.07)	0.016	3.14 (1.11–8.80)	0.030
3 (all high risk)	27	7.28 (2.66–20.0)	1.E-04	10.2 (3.43–30.3)	3.E-05
		Trend P = 9.E-07		Trend P = 4.E-07

^aAdjusted for stage, smoking history, age and sex, as well as race and cohort membership when appropriate. Upon restaging to AJCC 7th edition, there were 6 cases in the Norway cohort for which it could not be distinguished whether they were TNM stage IB or II. These are included in univariable analyses and excluded in multivariable analyses.

N: The number of available data for a particular variable in the univariable analysis.

NOTE: Bold, significant values < 0.05.